TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $7.64 billion. The enterprise value is $7.85 billion.
| Market Cap | 7.64B |
| Enterprise Value | 7.85B |
Important Dates
The next estimated earnings date is Monday, November 2, 2026, before market open.
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 141.85 million shares outstanding. The number of shares has decreased by -5.56% in one year.
| Current Share Class | 141.85M |
| Shares Outstanding | 141.85M |
| Shares Change (YoY) | -5.56% |
| Shares Change (QoQ) | -1.74% |
| Owned by Insiders (%) | 4.62% |
| Owned by Institutions (%) | 83.26% |
| Float | 135.24M |
Valuation Ratios
The trailing PE ratio is 19.46 and the forward PE ratio is 28.44. TG Therapeutics's PEG ratio is 1.28.
| PE Ratio | 19.46 |
| Forward PE | 28.44 |
| PS Ratio | 9.56 |
| Forward PS | 6.91 |
| PB Ratio | 12.65 |
| P/TBV Ratio | 12.65 |
| P/FCF Ratio | 439.70 |
| P/OCF Ratio | 427.62 |
| PEG Ratio | 1.28 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 57.50, with an EV/FCF ratio of 451.33.
| EV / Earnings | 17.77 |
| EV / Sales | 9.81 |
| EV / EBITDA | 57.50 |
| EV / EBIT | 57.56 |
| EV / FCF | 451.33 |
Financial Position
The company has a current ratio of 4.27, with a Debt / Equity ratio of 1.25.
| Current Ratio | 4.27 |
| Quick Ratio | 3.55 |
| Debt / Equity | 1.25 |
| Debt / EBITDA | 5.45 |
| Debt / FCF | 43.40 |
| Interest Coverage | 3.64 |
Financial Efficiency
Return on equity (ROE) is 100.28% and return on invested capital (ROIC) is 16.74%.
| Return on Equity (ROE) | 100.28% |
| Return on Assets (ROA) | 7.28% |
| Return on Invested Capital (ROIC) | 16.74% |
| Return on Capital Employed (ROCE) | 9.94% |
| Weighted Average Cost of Capital (WACC) | 12.54% |
| Revenue Per Employee | $2.00M |
| Profits Per Employee | $1.11M |
| Employee Count | 399 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 0.93 |
Taxes
| Income Tax | -339.89M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +69.33% in the last 52 weeks. The beta is 1.66, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | +69.33% |
| 50-Day Moving Average | 53.59 |
| 200-Day Moving Average | 39.50 |
| Relative Strength Index (RSI) | 50.04 |
| Average Volume (20 Days) | 1,770,252 |
Short Selling Information
The latest short interest is 30.11 million, so 21.23% of the outstanding shares have been sold short.
| Short Interest | 30.11M |
| Short Previous Month | 29.32M |
| Short % of Shares Out | 21.23% |
| Short % of Float | 22.26% |
| Short Ratio (days to cover) | 13.30 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $799.54 million and earned $441.49 million in profits. Earnings per share was $2.77.
| Revenue | 799.54M |
| Gross Profit | 658.60M |
| Operating Income | 136.33M |
| Pretax Income | 101.60M |
| Net Income | 441.49M |
| EBITDA | 136.45M |
| EBIT | 136.33M |
| Earnings Per Share (EPS) | $2.77 |
Balance Sheet
The company has $552.25 million in cash and $754.44 million in debt, with a net cash position of -$202.19 million or -$1.43 per share.
| Cash & Cash Equivalents | 552.25M |
| Total Debt | 754.44M |
| Net Cash | -202.19M |
| Net Cash Per Share | -$1.43 |
| Equity (Book Value) | 604.08M |
| Book Value Per Share | 4.26 |
| Working Capital | 877.19M |
Cash Flow
In the last 12 months, operating cash flow was $17.88 million and capital expenditures -$491,000, giving a free cash flow of $17.39 million.
| Operating Cash Flow | 17.88M |
| Capital Expenditures | -491,000 |
| Depreciation & Amortization | 123,000 |
| Net Borrowing | 492.66M |
| Free Cash Flow | 17.39M |
| FCF Per Share | $0.12 |
Margins
Gross margin is 82.37%, with operating and profit margins of 17.05% and 55.22%.
| Gross Margin | 82.37% |
| Operating Margin | 17.05% |
| Pretax Margin | 12.71% |
| Profit Margin | 55.22% |
| EBITDA Margin | 17.07% |
| EBIT Margin | 17.05% |
| FCF Margin | 2.17% |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.56% |
| Shareholder Yield | 5.56% |
| Earnings Yield | 5.78% |
| FCF Yield | 0.23% |
Analyst Forecast
The average price target for TG Therapeutics is $69.71, which is 29.36% higher than the current price. The consensus rating is "Buy".
| Price Target | $69.71 |
| Price Target Difference | 29.36% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 38.11% |
| EPS Growth Forecast (3Y) | 8.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:56.25 |
Scores
TG Therapeutics has an Altman Z-Score of 3.37 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.37 |
| Piotroski F-Score | 4 |